Development of ultra-miniaturized weak affinity chromatography coupled to mass spectrometry as a high throughput fragment screening method against wild-type and purified membrane proteins embedded in biomimetic membranes.

Date publication

juin 2025

Journal

Analytica chimica acta

Auteurs

Membres identifiés du Cancéropôle Est :
Dr WAGNER Renaud

Tous les auteurs :
Vidal FX, Gil J, Gregson M, Zeder-Lutz G, Hideux M, Lemoine J, Krimm I, Wagner R, Dugas V, Demesmay C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40221197

Résumé

Membrane proteins, which make up approximately 30 % of the proteome, are important drug targets but present many challenges in drug discovery, including limited production rates, low final yields of pure and functionally folded proteins, and instability in aqueous media. The problems encountered with membrane proteins are even more critical in the Fragment Based Drug Discovery, where the discovery of potential drug candidates is hampered by the limited availability of efficient methods for rapid screening of weak fragment-protein interactions.

Mots clés

Fragment-based drug discovery, Mass spectrometry, Membrane protein, Monolithic capillary column, Nanoliquid chromatography, Weak affinity chromatography

Référence

Anal Chim Acta. 2025 06 1;1353:343950